fda grants breakthrough status to imgn632 for blastic
List of drugs granted breakthrough therapy designation
Below is a list of drugs granted breakthrough therapy designation (BTD) by the FDA.. Drugs may be listed more than once as BTD can be awarded for multiple indications.
Get PriceNovel antibody-drug conjugate shows promising early
Based on initial findings the FDA granted breakthrough therapy designation to IMGN632 in October 2020. "While tagraxofusp is the only approved therapy for BPDCN so far it also has the potential for serious toxicity in the form of capillary leak syndrome so the favorable safety data seen thus far for IMGN632 is good news for CD123 agents
Get PriceImmunoGen Announces FDA Breakthrough stockwatch
ImmunoGen Inc. (Nasdaq IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell
Get PriceImmunoGen Announces FDA Breakthrough Therapy Designation
ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
Get PriceFDA Grants SL-401 Priority Review for Rare Hematologic Cancer
Aug 13 2018 · The FDA has granted a priority review designation to a biologics license application for SL-401 (tagraxofusp Elzonris) for the treatment of patients with blastic
Get PricePipeline CenterWatch
Oct 12 2020 · Investigational Device Exemption approved by the FDA AstraZeneca Farxiga (dapagliflozin) chronic kidney disease with and without type 2 diabetes Breakthrough Therapy designation granted by the FDA Immunogen IMGN632 relapsed or refractory blastic plasmacytoid dendritic cell neoplasm Breakthrough Therapy designation granted by the FDA
Get PriceFDA grants breakthrough status to IMGN632 for blastic
Oct 05 2020 · The FDA granted breakthrough therapy designation to IMGN632 for treatment of relapsed or refractory blastic plasmacytoid dendritic cell neoplasm according to the agent s manufacturer.
Get PriceImmunoGen s Rare Blood Cancer Candidate Gets Breakthrough
The FDA bestows a Breakthrough Therapy status on ImmunoGen s (IMGN) IMGN632 for treating patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm. Shares rise.
Get PriceFDA Grants SL-401 Priority Review for Rare Hematologic Cancer
The FDA has granted a priority review designation to a biologics license application (BLA) for SL-401 (tagraxofusp Elzonris) for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) according to Stemline Therapeutics the developer of the novel stemness inhibitor.
Get PriceList of drugs granted breakthrough therapy designation
Below is a list of drugs granted breakthrough therapy designation (BTD) by the FDA.. Drugs may be listed more than once as BTD can be awarded for multiple indications.
Get PriceClinical Profile of IMGN632 a Novel CD123-Targeting
• IMGN632 demonstrated a 29 (8/28) ORR with 5 complete responses including patients who had failed prior tagraxofusp-erzsMultiple durable responses observed in the absence of HSCT • FDA Breakthrough Therapy Designation (BTD) granted in R/R BPDCN • Enrollment is open for patients with R/R and frontline BPDCN. IMGN632 in BPDCN
Get PriceMore on IMGN632 in BPDCN IMGN Message Board Posts
Dec 22 2020 · Other agents are being studied as possible treatments for BPDCN including the BCL2 antagonist venetoclax (Venclexta) as well as other CD123 targeting agents including IMGN632 which has been granted breakthrough status by the FDA for treatment of relapsed or refractory BPDCN.
Get PriceImmunoGen Announces FDA Breakthrough Therapy Designation
ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm05.10.2020 ImmunoGen Announces FDA Breakthrough Therapy
Get PriceImmunoGen Presents Updated Findings from Phase 1/2 Study
05.12.2020ImmunoGen Inc. (Nasdaq IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer today announced that new safety and efficacy findings
Get PriceImmunoGen Announces FDA Breakthrough stockwatch
ImmunoGen Inc. (Nasdaq IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell
Get PriceImmunoGen Announces FDA Breakthrough stockwatch
ImmunoGen Inc. (Nasdaq IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell
Get PriceA Recap of FDA Approvals and Other Actions from October 2020
FDA Grants Breakthrough Therapy Designation to CD123-Directed Antibody-Drug Conjugate On October 5 2020 the FDA granted a Breakthrough Therapy Designation to the CD123-directed antibody-drug conjugate IMGN632 as treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasms.
Get PriceImmunoGen Announces FDA Breakthrough stockwatch
ImmunoGen Inc. (Nasdaq IMGN) a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell
Get PriceImmunoGen Presents Updated Findings from Phase 1/2 Study
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting Stocks NAS IMGN release date Dec 05 2020
Get PriceImmunoGen s Rare Blood Cancer Candidate Gets Breakthrough Tag
Oct 06 2020 · The FDA bestows a Breakthrough Therapy status on ImmunoGen s (IMGN) IMGN632 for treating patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm. Shares rise.
Get PriceNovel antibody-drug conjugate shows promising early
Novel antibody-drug conjugate shows promising early results in rare blood cancer Early study data shows 29 overall response rate favorable safety profile in blastic plasmacytoid dendritic cell
Get PriceStemline Therapeutics Announces that FDA Accepts ELZONRIS
Aug 13 2018 · ELZONRIS has completed a pivotal trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN) for which it was granted breakthrough therapy designation (BTD). The pivotal trial met its primary endpoint and a Biologics License Application (BLA) has been accepted for filing and granted Priority Review by the FDA. ELZONRIS is also being
Get PriceIMGN632 Investor Call
IMGN632 Novel CD123-Targeting ADC Active in BPDCN and AML • Novel Anti -CD123 AntibodyHigh affinity binding to CD123Unique epitope in extracellular domain • Novel IGN Payload (DGN549) 1DNA-alkylating activity single strand DNA breaks (vs. double strand)Uniform drug antibody ratio (DAR=2) • Novel Peptide Linker
Get PriceImmunoGen s IMGN632 nabs accelerated review for rare blood
The FDA designates ImmunoGen s (NASDAQ IMGN) IMGN632 a Breakthrough Therapy for the treatment of patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm a rare and
Get PriceImmunoGen Reports Recent Progress and 2020 Financial
Aligned with the US Food and Drug Administration (FDA) on a path to full approval for IMGN632 amending our ongoing 801 Phase 1/2 study with a new pivotal cohort of up to 20 frontline blastic
Get PriceImmunoGen s Rare Blood Cancer Candidate Gets Breakthrough Tag
The FDA bestows a Breakthrough Therapy status on ImmunoGen s (IMGN) IMGN632 for treating patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm. Shares rise.
Get PriceImmunoGen s Rare Blood Cancer Candidate Gets Breakthrough Tag
Oct 06 2020 · ImmunoGen Inc. IMGN announced that the FDA has granted a Breakthrough Therapy designation to its novel CD123-targeted antibody-drug conjugate (ADC) IMGN632 for the treatment of patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) a rare and aggressive form of blood cancer. The prestigious tag was based on results from the BPDCN cohort of
Get PriceImmunoGen gets FDA breakthrough therapy status for IMGN632
Oct 06 2020 · ImmunoGen has secured breakthrough therapy status from the US Food and Drug Administration (FDA) for its IMGN632 to treat patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). The US FDA s Centre for Drug Evaluation and Research. (Credit The U.S. Food and Drug Administration)
Get PriceImmunoGen (IMGN) Stock Price Quote News Stock Analysis
Apr 12 2021 · The FDA bestows a Breakthrough Therapy status on ImmunoGen s (IMGN) IMGN632 for treating patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm. Shares rise. 6 months agoZacks Investment Research
Get PriceImmunoGen Presents Updated Findings from Phase 1/2 Study
Dec 05 2020 · ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting FDA has granted IMGN632 Breakthrough Therapy
Get PriceImmunoGen (IMGN) Stock Price Quote News Stock Analysis
Apr 12 2021 · The FDA bestows a Breakthrough Therapy status on ImmunoGen s (IMGN) IMGN632 for treating patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm. Shares rise. 6 months agoZacks Investment Research
Get Price
